CASSAVA SCIENCES INC.

Cassava Sciences Selects Clinical Research Organization for Phase 3 Clinical Program in Alzheimer’s Disease

21 Jun 2021 15:10:00 By Nasdaq GlobeNewswire

Cassava Sciences Provides Mid-Year Corporate Update, Clinical Development Progress and Announces Guidance on Clinical Data Release

21 Jun 2021 07:30:00 By Nasdaq GlobeNewswire

Cassava Sciences to Present at the Raymond James 2021 Human Health Innovation Conference

17 Jun 2021 15:01:00 By Nasdaq GlobeNewswire

Cassava Sciences Announces the Appointment of Richard J. Barry to its Board of Directors

14 Jun 2021 07:30:00 By Nasdaq GlobeNewswire

Cassava Sciences to Participate in Q&A Panel Discussion on Alzheimer’s Disease

24 May 2021 07:30:00 By Nasdaq GlobeNewswire

Cassava Sciences Announces Initiation of Cognition Maintenance Study in Alzheimer’s disease

10 May 2021 07:30:00 By Nasdaq GlobeNewswire

Cassava Sciences Invited to Participate in B. Riley Securities’ Neuroscience Conference

27 Apr 2021 07:30:00 By Nasdaq GlobeNewswire

Cassava Sciences Invited by the NIH to Participate in Sachs 4th Annual Neuroscience Innovation Forum

26 Apr 2021 07:30:00 By Nasdaq GlobeNewswire

Cassava Sciences Reports First Quarter 2021 Financial Results and Announces Guidance on Clinical Data Release

21 Apr 2021 07:30:00 By Nasdaq GlobeNewswire

Cassava Sciences Announces Full-year 2020 Financial Results and Business Highlights

23 Mar 2021 07:30:00 By Nasdaq GlobeNewswire

Cassava Sciences Announces Pharmaceutical Supply Agreement for Simufilam

09 Mar 2021 08:00:00 By Nasdaq GlobeNewswire

Cassava Sciences to Present at the H.C. Wainwright Global Life Sciences Conference

08 Mar 2021 07:30:00 By Nasdaq GlobeNewswire

Cassava Sciences to Present at SVB Leerink Global Healthcare Conference

23 Feb 2021 07:30:00 By Nasdaq GlobeNewswire

Cassava Sciences Announces Positive End-of-Phase 2 Meeting with FDA and Outlines Pivotal Phase 3 Program for Simufilam in Alzheimer’s Disease

22 Feb 2021 07:30:00 By Nasdaq GlobeNewswire

Cassava Sciences Announces Closing of $200 Million Registered Direct Offering

12 Feb 2021 16:08:17 By Nasdaq GlobeNewswire

Cassava Sciences Announces $200 Million Registered Direct Offering of Common Stock

10 Feb 2021 05:15:06 By Nasdaq GlobeNewswire

Cassava Sciences Announces Significant Program Progress and Expected Key Milestones in 2021 for Its Clinical Program in Alzheimer’s Disease

08 Feb 2021 07:30:00 By Nasdaq GlobeNewswire

Cassava Sciences’ Simufilam Improves Cognition and Behavior in Alzheimer’s Disease in Interim Analysis of Open-label Study

02 Feb 2021 07:30:00 By Nasdaq GlobeNewswire

Cassava Sciences Appoints Dr. James Kupiec as Chief Clinical Development Officer

04 Jan 2021 07:30:00 By Nasdaq GlobeNewswire